These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2186055)

  • 1. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
    Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
    J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
    Wang C; Lam KS; Arceo E; Chan FL
    J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
    Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
    J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group.
    Sassolas G; Harris AG; James-Deidier A
    J Clin Endocrinol Metab; 1990 Aug; 71(2):391-7. PubMed ID: 2199479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly.
    Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW
    Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of octreotide in acromegaly on insulin resistance.
    Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
    Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report.
    Atkinson AB; McKnight JA; McCance DR; Bell PM
    Horm Res; 1990; 33 Suppl 1():7-11; discussion 11-2. PubMed ID: 2358295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly.
    Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J
    J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.